Engineered Escherichia coli Nissle 1917 secreting anti-TNF-α nanobody as a single-strain live biotherapeutic for inflammatory bowel disease - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Genetically Modified Escherichia coli Nissle 1917 Producing Anti-TNF-α Nanobody as a Novel Single-Strain Live Biotherapeutic for Treating Inflammatory Bowel Disease

  • By

  • Qiumei Zhu

  • Shitao Feng

  • Zhende Yan

  • Zijian Wang

  • Xinran Huang

  • Changning Sun

  • Bingqiang Zhang

  • Xinrui Li

  • Yuchao Gu

  • July 2, 2026

Share

Original Source(s)

Engineered Escherichia coli Nissle 1917 secreting anti-TNF-α nanobody as a single-strain live biotherapeutic for inflammatory bowel disease

  • by Qiumei Zhu, Shitao Feng, Zhende Yan, Zijian Wang, Xinran Huang, Changning Sun, Bingqiang Zhang, Xinrui Li, Yuchao Gu

  • July 2, 2026

Related Content

Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis

TNFAIP3/A20 dysfunction drives innate and sterile hyperinflammation

Diagnostic performance of fecal eosinophil-derived neurotoxin and lipocalin-2 in pediatric inflammatory bowel disease